GSK

GSK plc

Phase 2 AI-extracted

Mo-Rez ADC

difficult-to-treat endometrial and ovarian cancer

Resolved

69days ago

Phase 2 readout · Apr 29, 2026

What's at stake Phase 2 trial results for Mo-Rez ADC in difficult-to-treat endometrial and ovarian cancer are due Apr 29, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 6-K verified 13h ago

“Phase I data for Mo-Rez ADC in difficult-to-treat endometrial and ovarian cancer supports initiation of 5 phase III trials in 2026.”

Add to calendar Post on X Reddit

Provenance